Introduction {#Sec1}
============

Mutations in the *ras* proto-oncogenes (*H-ras*, *N-ras*, *K-ras*) are the most common genetic aberrations in human tumors, occurring in 20--30% of all tumors; although this figure varies considerably depending on the tumor entity. The most frequently observed *ras* mutations occur in codons 12, 13, and 61, with these mutations disrupting the GTPase function of Ras. Although the mutated Ras still forms a complex with regulatory GTPase activating proteins (GAPs), conversion of guanosine-5′-triphosphate (GTP) to guanosine-5′-diphosphate (GDP), i.e., Ras inactivation, is attenuated. This blockade leads to a longer half-life of the active GTP-binding form of Ras. Besides mutations in codons 12, 13, and 61, sporadic mutations have been described in codons 116, 117, 119, and 146. These mutations decrease the protein's affinity towards nucleotides, leading to an exchange in favor of cytosolic GTP, of which there is a ten-fold higher level than GDP. In addition, the binding of hydrolysis-enhancing GAPs is inhibited. Moreover it has been shown that mutations in codons 59 and 63 activate the transforming potential of the H-*ras* gene \[[@CR1]\] but are of little clinical relevance. Hence, all known mutations lead to an accumulation of constitutively active Ras and uninterrupted signal transfer. In malignant hematopoietic diseases, activating Ras mutations occur most commonly in myeloid disorders, in myelodysplastic syndrome (MDS) and AML, with the level of Ras activation ranging from 6 to 37%. The mutations occur largely in N-*ras* codons 12, 13, and 61, and in K-*ras* codon 12; H-*ras* mutations are rarely seen in this entity. The most common mutation is a G→A mutation in codon 12 \[[@CR2], [@CR3]\]. Activated Ras mutations appear to play an important part in the transformation from MDS to AML, and a high percentage of patients with MDS-based AML develop Ras mutations in the course of their disease \[[@CR4]\]. Furthermore, a prospective study showed that MDS patients with a confirmed *ras* mutation have a significantly higher risk of developing AML \[[@CR5]\].

In addition to mutations in the *ras* gene, Ras can be activated by constitutively active proto-oncogenes and inactivated by tumor suppressor genes \[[@CR6]\]. Several receptor tyrosine kinases and non-receptor tyrosine kinases signal via the Ras transduction pathway. Point mutations in the CSF-1 receptor (c-FMS) are found in 10--20% of all AML and MDS patients \[[@CR7]\]. Another common defect in AML and MDS is tandem duplications in the FLT3 receptor, which occur in 20--25% of all AML cases. Simultaneous mutations in N-*ras* and FLT3 are very rare \[[@CR8]\]. Members of the c-Kit/c-FMS receptor kinase family (e.g., c-Kit, c-FMS, FLT3) associate with proteins of the Ras/MAPK signal transduction pathway (e.g., Grb-2 and Shc). Hence, their activation could activate Ras \[[@CR9]\].

The Bcr-Abl fusion protein occurs in 95% of chronic myelogenous leukemia (CML) cases and in 10% of ALL cases. Although *ras* mutations in CML are rare, several experiments have shown that Ras activation via the constitutively active Bcr-Abl protein plays an important role. Inhibition of Ras activity by antisense oligonucleotides, microinjection of a blocking monoclonal antibody, or overexpression of dominant-negative Ras-GAP block transformation by Bcr-Abl \[[@CR10], [@CR11]\]. Another Abl fusion protein, Tel-Abl, is found in AML featuring a t(12;9) translocation \[[@CR12], [@CR13]\]. Other fusion proteins that activate the Ras/MAPK transduction pathway are: (1) the Npm-Alk fusion protein in anaplastic large cell non-Hodgkin's lymphoma featuring a t(2;5) translocation \[[@CR14], [@CR15]\]; and (2) Tel-PDGFR---a fusion protein comprising the transcription factor Tel (translocation, Ets, leukemia) and PDGFR, which occurs in a subpopulation of chronic myelomonocytic leukemia (CMML) and features a t(5;12) translocation \[[@CR12]\].

A number of tumor repressor genes trigger dysregulation of Ras activity. These include the Ras-GAP NF-1, which is mutated in the autosomal dominant form of neurofibromatosis type 1 \[[@CR16], [@CR17]\]. In adolescents, neurofibromatosis type 1 is associated with an increased risk of developing myeloproliferative disorders, particularly JMML. In 15% of children with JMML not showing clinical symptoms of neurofibromatosis, inactivating NF-1 mutations have been found \[[@CR18]\]. Furthermore, 15--30% of JMML cases that lack the NF-1 mutation present with activating *ras* mutations \[[@CR19]\]. Mutations in both the *ras* and NF-1 genes are very rare and seem to be mutually exclusive \[[@CR20]\].

Somatic PTPN11 mutations occur in approximately 35% of JMML patients \[[@CR18], [@CR21]--[@CR22]\]. PTPN11 encodes the tyrosine phosphatase SHP-2 which transmits signals of growth factor receptors to Ras and other effectors. Thus, Ras can be activated by either an activating mutation in the *ras* gene or by mutations in proteins that signal through Ras. Gain-of-function mutations of RAF1, a downstream Ras effector, cause Noonan syndrome in patients who do not have a mutation of Ras or upstream effectors \[[@CR23], [@CR24]\].

In this study, Ras activity determined by the ratio of Ras-GTP to Ras-GDP has been compared with the mutational status of the Ras gene in the hematopoietic cells of the patients.

Materials and methods {#Sec2}
=====================

Patient samples from bone marrow aspirates or peripheral blood were collected between 1999 and 2002 after informed consent had been obtained. Approximately 10 ml of peripheral blood or 1 ml of bone marrow was obtained from normal subjects and from children with B-ALL according to a procedure approved by the UFMC IRB and from children with T-ALL according to approved protocols. Samples were shipped overnight with the bone marrow samples diluted 1:2 in RPMI medium. To generate peripheral WBCs and nucleated bone marrow cells, red cells were lysed in 0.9% ammonium acetate according to standard procedures, and to generate peripheral blood lymphocytes, whole blood was applied to a Ficoll gradient as previously described. Some of the samples were cells isolated on a Ficoll gradient and frozen in 10% DMSO; these samples were washed once in PBS before further processing. As discussed later in Results, none of these isolation procedures altered the activation state of Ras.

Samples from 23 patients were used: seven patients with AML, four patients with MPS (one osteomyelofibrosis (OMF), three CML), four patients with JMML, four patients with ALL and four with lymphoma including plasma cell leukemia. Except for the four patients with JMML, all patients were being treated in the Department of Medicine I at the University of Freiburg Medical Center.

Because of problems associated with using ^32^PO~4~ to assess Ras activation, we used biochemical non-radioactive methods for measuring GTP and GDP bound to Ras family proteins as described before \[[@CR25], [@CR26]\]. Ras was immunoprecipitated with the rat monoclonal antibody Y13-259. Absolute amounts of GTP and GDP were measured in coupled enzymatic reactions. GTP was measured by converting it to ATP using the enzyme nucleoside diphosphate kinase (NDPK, Sigma St. Louis, MO) in the presence of ADP. The resulting ATP was measured by firefly luciferase (Calbiochem, San Diego, CA) in a photon counting luminometer. The firefly luciferase system is extremely sensitive, allowing detection of 1 fmol of GTP. To measure GDP, we converted it to GTP using the enzyme pyruvate kinase (PK, Sigma St. Louis, MO) with phosphoenolpyruvate serving as a source of high-energy phosphate.

As positive controls, HL-60 cells (AML FAB M2) with a known N-*ras* mutation in codon 61 (CAA→CTA) were used. As negative controls with known wildtype *ras*, the myelogenous cell line U937 and the pre-B-ALL cell line 697 were used. Murine 3T3 fibroblasts were used both as a negative and a positive control, the latter after being transfected with an activated H-Ras Val12 vector (Table [1](#Tab1){ref-type="table"}). Table 1Results of Ras activity determination and mutation analysis of control cellsCell lineGTP/(GTP+GDP) in %SequenceHL-6020.9N-*ras* codon 61 CAA-CTA3T3 V1238.0H-*ras* V126976.3WTU9370.8WT3T3 WT8.7WTWBC^a^3.2WT^a^WBCs isolated from a healthy donorGTP activation of Ras was measured in six different cell lines as positive controls, for which HL-60 cells (AML FAB M2) harbouring a known N-*ras* mutation were used as well as 3T3 transfected with a plasmid containing H-*ras* V12. Negative controls were U937 (myelogenous, WT), pre-B-ALL derived 697 cells as well as WT NIH3T3 cells. In addition WBCs from the peripheral blood of a healthy donor were analyzed.

Genomic DNA was isolated using the commercially available "QIAamp DNA Blood Mini Kit" (QIAGEN GmbH, Hilden, Germany). Amplification was performed with K-*ras* and N-*ras* specific primers containing 5′ universal M13 primer sequence attached, which were then used for genomic sequencing (ABI PRISM® BigDye Terminator Cycle Sequencing Kit and ABI310 Genetic Analyzer-System, Applied Biosystems, Foster City, USA)

Results {#Sec3}
=======

Frequency of N-ras and K-ras mutations in 23 patients with several hematological disorders and in one healthy control

Table [2](#Tab2){ref-type="table"} shows results of Ras activation in peripheral blood and bone marrow WBCs from a total of 23 patients: seven with AML, four with ALL, two with CML, four with JMML and one with lymphoma. No diagnosis could be given to five of the patients. Table 2Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphomaPatient \#Diagnosis1AML19.8MutationN-*ras*exon 112GGT-TGT2AML1.6WT3AML4.6WT4AML1.9WT5AML0.6WT6AML2.1WT7AML1.2MutationN-*ras*exon 261CAA-AAA8ALL2.5WT9ALL2.7WT10ALL5.1WT11ALL1.5WT12CML2.4WT13CML5.9WT14lymphoma15.4MutationN-*ras*exon112GGT-GAT15JMML38.6WT16JMML11.7Nd17JMML16.4Mutationnd18JMML1.1Mutationnd19nd32.7WT20nd1.7WT21nd7.3WT22nd2.9Nd23nd4.9NdOverall, the sequences of *n-, k-ras* were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).

Mutation analysis confirmed mutations in the positive controls, and showed mutations in two of the seven AML samples (29%), one in codon 12 (exon1) and one in codon 61 (exon2). The latter data are consistent with the mutation frequencies reported in the literature. Our results are also in accordance with recent data indicating that the frequency of Ras mutations in AML and MDS has been overestimated in the past (M. Lübbert, personal communication).

In the samples from patients with MPS again no mutation of Ras could be detected, a finding which has been previously explained by constitutive Ras activation via the uncontrolled Bcr-Abl signal upstream of Ras \[[@CR31]\]. None of the four ALL samples showed a mutation. This is compatible with the lower frequency of *ras* mutations in this entity. *Ras* mutations were also found in two of the JMML samples. A N-Ras mutation has been found in codon 12 (exon 1) of a sample from a patient with a plasma cell leukemia. Frequency of Ras activation in 23 patients with several hematological disorders and in one healthy control (Fig. [2](#Fig2){ref-type="fig"}) and in six cell lines (Fig. [1](#Fig1){ref-type="fig"})Fig. 1Ras Activation in 12 different determinations (dots) of Ras activation \[GTP/(GDT+GTP)%\] of control cells lines according to their mutational status. Samples with known WT sequences are shown separate from samples with known activating mutation. The 95% CI are shown by *bars*. Average ras activation in WT versus mutation samples is 4.75% (0.8--8.7%) vs. 23.06% (12.7--38%) respectively. This difference is significant (*p* = 0.006; *t*-test, ungrouped)

Recent mathematical models of the Ras signaling pathway supported by experimental observations have underlined the function of Ras as a 'molecular switch' in signal transduction. Given four hypothetical disruptions in Ras signaling---GAP insensitivity, reduced GTPase activity, increased effector affinity and competitive inhibition of Ras-GAP by Ras RasVal12---it was hypothesized that cells harboring a heterozygous *ras* mutation resulting in a GAP-insensitive RasVal12 show an hypothetical activation (total Ras bound GTP) of approximately 28%. By contrast, wildtype (WT cells) should show an activation of approximately 5% \[[@CR27]\].

In Fig. [1](#Fig1){ref-type="fig"}, Ras activation from 12 different determinations \[GTP/(GDT+GTP)%\] were grouped according to their mutational status. The 95% CIs are represented by bars. Average Ras activation in WT was 4.75% (0.8--8.7%) vs. 23.06% (12.7--38%) respectively. This difference proved significant (*p* = 0.006; *t*-test, ungrouped).

In Fig. [2](#Fig2){ref-type="fig"}, Ras activation of patient samples is shown according to their mutational status. Patient samples (*n* = 23) are separated by their hematological entity. A patient sample was considered to contain activated Ras if the activation level was within the 95% CI of the positive controls, and negative if it was within the 95% CI of the negative controls. Both 95% CIs of negative and positive control cells are indicated by bars. Fig. 2Ras activation of patient samples according to their mutational status. Numbers in **bold** represent average levels of Ras activation. A patient sample was considered to have activated Ras if activation level was within the 95% confidence interval (CI) of the positive controls, and negative for Ras activation if it was within the 95% CI of the negative controls. The 95% CIs of the positive and negative controls are represented by *vertical bars*

The average activation of patient samples with proven *ras* mutations (*n* = 5) was 10.8% (1.1--19.8%; 95% CI, 0.333--23.3). The average activation of patient samples with *ras* WT sequence was 7.41% (0.6--38.6%; 95% CI, 1.32--13.44). Since the 95% CIs overlap in this analysis, the difference is not significant (*p* = 0.565, *t*-test ungrouped). Discrepancy between Ras activation and ras activating mutations

One of the two samples with activating Ras from patients with AML, the a N-ras mutation of codon 61 in exon 2 resulting in a CAA-AAA sequence, did not show a higher percentage of GTP-Ras which would be indicative of an activation of the protein, whereas the N-ras mutation in codon 12 of Exon resulting in a GGT-TGT sequence was correlated with a GTP/GTP+GDP ratio of 19.8%. In the samples from patients with JMML, one sample had no increased Ras-GTP in spite of an activating mutation. One wildtype sample showed a Ras-GTP percentage of 38.6% without an activating Ras-mutation.

Discussion {#Sec4}
==========

The frequencies of mutations found in our study for different forms of hematological malignancies do not reach significance levels due to the low number of samples, but in general they reflect the tendencies found in previous reports \[[@CR35]\].

We showed that cell lines with known constitutively activating *ras* mutations had significantly higher levels of Ras-GTP (mean activation 23.1%, *p* = 0.006) than did cell lines with WT-Ras (mean activation 4.8%). These data show the high degree of selectivity of the assay in distinguishing between cells with activated and non-activated Ras and are consistent with hypothetical and observed activations \[[@CR28]\]. Determination of a threshold for positive Ras activation in patient samples is difficult. Given the aspect of Ras functioning as 'molecular switch' and taking into account the expected heterogenity of patients' primary cells (Ras isoforms, clonality, etc.) we established two ranges (95% CIs) of cell populations with either WT *ras* or mutated *ras* in order to be able to classify patients' values as activated or not activated in the setting of our assay. A patient sample was considered to have an activated Ras if the activation level was within the 95% CI of the positive controls. Three of the five patient samples (60%) with proven *ras* mutations belong in this category. On the other hand, 12 of 14 patient samples (approximately 86%) with wildtype sequence are within the 95% CI of the negative controls.

The lack of intermediate values reflects the function of Ras as a 'molecular switch'. Therefore, patient samples with increased Ras activation lacking a mutational activation are of interest for further analysis of the Ras signal transduction cascade, since various up- and downstream effectors contribute to Ras activation.

Ras mutations were found in hematological neoplasia known to have mutated Ras: two of six AML cases, one of two plasma cell leukemias (PCL), and two of four JMML cases. In two of the five patients with Ras mutations, Ras showed increased activation. However, one AML and one JMML sample showed noticeably low levels of activation though harboring a *ras* mutation.

In addition to technical difficulties with the applied highly sensitive enzyme-based method, heterogeneity of the underlying patients' samples has to be taken into account. In further studies, the issue of clonality of samples could be overcome by pre-sorting cells, e.g., by flourescence activated cell sorter (FACS). Another explanation might be additional compensatory factors bypassing Ras such as, for example, by GAP \[[@CR29]\] regulation or compensatory up-regulation of WT-Ras.

In the patient sample with a Ras activation of 32.7% but no underlying mutation, the diagnosis was pre-B-ALL. In this context, CD40-stimulated Ras activation in the early developmental stages of B-cells has been described \[[@CR30]\].

Assessing Ras quantitatively in hematopoietic neoplasia may provide a basis for understanding the role of Ras in various signal transduction pathways and may provide new routes toward targeted treatment strategies. The most promising category influencing Ras signalling is farnesyltransferase inhibitors (FTIs), which inhibit the attachment of the farnesyl moiety to the Ras protein \[[@CR32], [@CR33]\]. In addition, drugs which interfere with the interaction of the farnesyl group with the cell membrane, such as farnesyl thiosalicylic acid, also influence the activity of Ras on a protein level \[[@CR34]\].
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